SCHEMBL31395699

SCHEMBL31395699

Cc1ccc(S(=O)(=O)n2ccc3c(-c4cncc(Oc5ccc(F)cc5)c4)cn(C)c(=O)c32)cc1

nearest known ligand 0.56

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
▸ BRD4 O60885 16/20 0.56
▸ PARG Q86W56 1/20 0.35
▸ XDH P47989 2/20 0.35
▸ PRMT5 O14744 1/20 0.35
▸ WDR77 Q9BQA1 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31589671 0.84 BRD4 (0.56) BRD4PARG
SCHEMBL31395489 0.83 BRD4 (0.59) BRD4
SCHEMBL31395483 0.82 BRD4 (0.54) BRD4
SCHEMBL31395704 0.80 BRD4 (0.52) BRD4
SCHEMBL31395392 0.80 BRD4 (0.53) BRD4
SCHEMBL31589747 0.78 BRD4 (0.55) BRD4
SCHEMBL31590455 0.78 BRD4 (0.58) BRD4
SCHEMBL31395367 0.76 BRD4 (0.47) BRD4
SCHEMBL31395287 0.76 BRD4 (0.45) BRD4
SCHEMBL17492897 0.75 BRD4 (0.52) BRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4739307-A2 TARGETED EPIGENETIC THERAPIES FOR DISORDERS OF PROGRANULIN DEFICIENCY The General Hospital Corporation (US) 2026-05-13 — — EP disclosed
WO-2025010291-A2 TARGETED EPIGENETIC THERAPIES FOR DISORDERS OF PROGRANULIN DEFICIENCY THE GENERAL HOSPITAL CORPORATION (US) 2025-01-09 — — WO disclosed
Send feedback